Biomedical and Precision Health

Biomedicine and precision health are among Taiwan's key strategic areas. In 2017, Taiwan launched the “5+2 Innovative Industries Plan – Biomedical Industry Innovation Program,” driving domestic biomedical innovation and transformation. In 2020, Taiwan further incorporated the “Six Core Strategic Industries – Precision Health Industry,” with the goal of establishing itself as a global benchmark in precision health and technological epidemic prevention. In May 2024, following the policy framework of the “National Project of Hope,” Taiwan continues to coordinate inter-ministerial efforts to advance biomedical and precision health policies, strengthen the national biomedical capacity, upgrade industries, and enhance public well-being.

Leveraging Taiwan's strengths in semiconductor and its world-class healthcare system, Taiwan integrates cutting-edge technologies such as AI and big data, with regulatory adaptation and talent cultivation as the foundation. These efforts accelerate the development of innovative medical products and services, enabling technology policies to both foster industrial growth and meet societal needs. The main strategies are as follows:

1. Promoting Interdisciplinary Innovation：Taiwan has integrated technologies such as AI and semiconductors to accelerate drug development and biomedical chip applications; developed portable devices for home-based care, clinical diagnostic support systems, and other public health solutions to improve medical services, enhance industrial competitiveness, and advance public health and welfare.

2. Advancing Healthcare through Data：Taiwan is establishing global standards for healthcare data interoperability to drive the digital transformation of medical institutions; developing citizen-centered health data services; and integrating and analyzing biomedical big data to support improved clinical decision-making and pharmaceutical R&D. These efforts aim to support industrial development, while ensuring data privacy and security.

3. Expanding International Collaboration：Taiwan is actively establishing partnerships to develop Clinical Research Organization (CRO) services; enhancing translational research and clinical trial capabilities with global reach; and facilitating validation of Taiwan's medical products in domestic and international medical institutions to accumulate real-world evidence and accelerate international market access. Such initiatives position Taiwan as a key hub in the global biomedical landscape.

This policy will continue to place public health needs at its core and foster a supportive biomedical ecosystem through inter-ministerial collaboration. By leveraging Taiwan's existing technological strengths, the government will integrate emerging innovations across disciplines through public-private partnerships to accelerate the implementation of biomedical and precision health applications, strengthen industrial resilience, and shape Taiwan's sustainable competitiveness.